TME Pharma Provides Results of Final Exercise of Warrants Y

Additional €854K Raised and Extension of Cash Runway From May Into July 2024

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the final exercise of Warrants Y and an update on the outstanding number of ordinary shares, Warrants Y and Warrants Z. The exercise of 8,539,955 Warrants Y has triggered the issuance of 3,415,982 new shares for gross proceeds of €853,995.50. The net proceeds from the exercise extend the company’s cash runway from May 2024 into early July 2024.

"We are very pleased to announce the results of our latest successful warrant exercise, which reflects strong support demonstrated by a very high participation from our existing shareholders, extending our financial visibility into early July – well past the upcoming regulatory milestones," said Aram Mangasarian, CEO of TME Pharma. "We would like to thank our shareholders for their ongoing support and confidence in our mission. We believe that the recent termination of our convertible debt program and the end of the company's reliance on convertible bond financing have alleviated pressure on the share price and contributed to the success of this exercise. We are now looking forward to achieving our next targeted clinical and regulatory milestones, notably approval of the Investigational New Drug application for NOX-A12 in glioblastoma and a response to our Fast Track request targeted by quarter’s end, both of which are important milestones in advancing the development of our lead asset to become the best available therapy for aggressive brain cancer patients."

When exercising 5 Warrants Y held, a holder was entitled to subscribe for 2 ABSA Z at an exercise price of €0.25 per ABSA Z, each comprised of one new ordinary ALTME share and one Warrant Z (Bon de souscription d’actions Z). As a result of the exercises that took place during the final exercise period between February 10-16, 2024, 3,415,982 new ordinary shares and 3,415,982 Warrants Z are being issued by TME Pharma and settled today. Warrants Y that were not exercised by February 16, 2024, have become null and void. The following numbers of TME Pharma securities are thus issued and outstanding: